{"id":3083,"date":"2026-08-23T19:11:53","date_gmt":"2026-08-23T19:11:53","guid":{"rendered":"https:\/\/stagingen.saffrona.eu\/?p=3083"},"modified":"2026-10-11T12:18:34","modified_gmt":"2026-10-11T12:18:34","slug":"saffron-tolerability","status":"publish","type":"post","link":"https:\/\/www.saffrona.eu\/en\/saffron-tolerability\/","title":{"rendered":"Saffron Tolerability: What 102 Clinical Trials Show"},"content":{"rendered":"\n<article class=\"saffrona-academy-story\"><style>.saffrona-academy-story{max-width:780px;margin:auto;color:#343039;font-size:17px;line-height:1.85}.saffrona-academy-story h2{color:#56346b;font-size:clamp(25px,3vw,32px);line-height:1.3;margin:48px 0 18px}.saffrona-academy-story h3{color:#56346b;font-size:21px;margin-top:28px}.saffrona-academy-story p{margin:0 0 20px}.saffrona-academy-story a{color:#684180;text-decoration:underline;text-underline-offset:3px}.saffrona-academy-story .academy-note{background:#f6f1f8;border-left:3px solid #805698;padding:24px;margin:28px 0;border-radius:0 12px 12px 0}.saffrona-academy-story nav{background:#faf8f5;border:1px solid #e8e0eb;padding:24px;border-radius:14px}.saffrona-academy-story figure{margin:32px 0}.saffrona-academy-story img{width:100%;height:auto;border-radius:16px}.saffrona-academy-story figcaption{font-size:13px;color:#706876;margin-top:10px}.saffrona-academy-story ul{padding-left:22px}.saffrona-academy-story li{margin:8px 0}@media(max-width:600px){.saffrona-academy-story{font-size:16px;line-height:1.8}.saffrona-academy-story nav,.saffrona-academy-story .academy-note{padding:20px}.saffrona-academy-story h2{margin-top:36px}}.saffrona-academy-story .academy-table{overflow-x:auto;margin:24px 0}.saffrona-academy-story table{width:100%;border-collapse:collapse;font-size:15px;line-height:1.6}.saffrona-academy-story th,.saffrona-academy-story td{padding:12px 14px;border-bottom:1px solid #e8e0eb;text-align:left;vertical-align:top}.saffrona-academy-story th{background:#f2ebf5;color:#56346b}.saffrona-academy-story details{border-bottom:1px solid #e8e0eb;padding:18px 0}.saffrona-academy-story summary{font-weight:600;color:#56346b;cursor:pointer}.saffrona-academy-story details p{margin:14px 0 0}<\/style>\n<aside class=\"academy-note\"><strong>The short answer<\/strong><p><strong>Saffron was generally well tolerated in most of the clinical studies reviewed.<\/strong> A systematic review published in 2026 examined 102 clinical trials and one case report. Most reported symptoms were mild and temporary. Gastrointestinal complaints were most common, followed by headache, fatigue, dizziness and changes in sleep.<\/p><p>The authors calculated a descriptive figure of approximately 17.5% from 441 reported events among 2,520 participants. This is <strong>not an established individual rate of side effects<\/strong>: not every event was caused by saffron, and one person may have reported more than one event. Products, doses, study duration and safety monitoring also differed considerably.<\/p><\/aside>\n<nav aria-label=\"Article contents\"><strong>Explore the evidence<\/strong><ul><li><a href=\"#review\">What the review included<\/a><\/li><li><a href=\"#rate\">What the 17.5% figure means<\/a><\/li><li><a href=\"#symptoms\">Reported symptoms and causality<\/a><\/li><li><a href=\"#products\">Products, doses and long-term use<\/a><\/li><li><a href=\"#medicines\">Medicines and groups needing caution<\/a><\/li><li><a href=\"#limits\">Evidence gaps and culinary use<\/a><\/li><li><a href=\"#faq\">Frequently asked questions<\/a><\/li><\/ul><\/nav>\n<h2>What does tolerability mean in clinical studies?<\/h2><p>Saffron tolerability describes how often, and in what form, unwanted symptoms occur while people take saffron or a saffron preparation. Good tolerability does not automatically mean that a product is safe for every person, at every dose or for any length of time.<\/p><p>Clinical studies record health events that occur during an intervention. An <em>adverse event<\/em> does not necessarily result from the product being studied. Three statements must be distinguished:<\/p><ol><li>A symptom occurred while someone was taking saffron.<\/li><li>The symptom might be related to saffron.<\/li><li>A causal relationship with saffron was established.<\/li><\/ol><p>The review mainly addresses the first level: events reported during the use of different saffron preparations.<\/p>\n<h2 id=\"review\">How well was saffron tolerated in 102 clinical trials?<\/h2><p>Overall, saffron appeared mostly well tolerated at the amounts used in clinical studies. Most documented symptoms were described as mild to moderate and temporary.<\/p><p>The <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/hsr2.72212\" target=\"_blank\" rel=\"noopener\">systematic review of Crocus sativus safety<\/a>, published in <em>Health Science Reports<\/em> in 2026, included:<\/p>\n<div class=\"academy-table\"><table><thead><tr><th scope=\"col\">Feature<\/th><th scope=\"col\">Finding<\/th><\/tr><\/thead><tbody><tr><td>Clinical trials<\/td><td>102<\/td><\/tr><tr><td>Additional case reports<\/td><td>1<\/td><\/tr><tr><td>Trials providing safety information<\/td><td>79<\/td><\/tr><tr><td>Trials without adverse-event information<\/td><td>23<\/td><\/tr><tr><td>Saffron participants in trials with safety information<\/td><td>2,520<\/td><\/tr><tr><td>Reported events<\/td><td>441<\/td><\/tr><tr><td>Formal meta-analysis<\/td><td>No<\/td><\/tr><tr><td>Literature search ended<\/td><td>August 2024<\/td><\/tr><\/tbody><\/table><\/div>\n<p>The trials involved different populations, including healthy adults and people with psychiatric, neurological, metabolic, cardiovascular or inflammatory conditions.<\/p><p>The interventions also varied. They included ground saffron stigmas, aqueous extracts, alcoholic extracts, hydroalcoholic extracts, capsules, tablets and other formulations. Studies ranged from a single dose or a few days to twelve months.<\/p>\n<h2>How many trials actually reported safety information?<\/h2><p><strong>Only 79 of the 102 trials provided usable adverse-event information.<\/strong> Almost a quarter did not report whether or how symptoms were recorded.<\/p>\n<div class=\"academy-table\"><table><thead><tr><th scope=\"col\">Safety reporting<\/th><th scope=\"col\">Trials<\/th><th scope=\"col\">Proportion<\/th><\/tr><\/thead><tbody><tr><td>One or more events reported<\/td><td>44<\/td><td>About 43.1%<\/td><\/tr><tr><td>No events reported<\/td><td>35<\/td><td>About 34.3%<\/td><\/tr><tr><td>No event information<\/td><td>23<\/td><td>About 22.5%<\/td><\/tr><tr><td>Total<\/td><td>102<\/td><td>100%<\/td><\/tr><\/tbody><\/table><\/div>\n<p>The 23 trials without safety information cannot be interpreted as trials \u201cwithout side effects\u201d. It is unclear whether no symptoms occurred or whether they were not systematically recorded and published.<\/p><p>Passive reporting can underestimate mild symptoms. Participants may not spontaneously mention nausea, headaches or changes in sleep. Active questioning is more likely to capture these events.<\/p>\n<h2 id=\"rate\">What does the 17.5% figure really mean?<\/h2><p><strong>It is a descriptive ratio, rather than a precise individual side-effect rate.<\/strong> Across the 79 trials with safety information, the authors recorded 2,520 saffron participants and 441 reported adverse events: approximately 17.5 events per 100 participants.<\/p><p>This calculation does not reliably establish how many individuals experienced a side effect caused by saffron. The reasons include:<\/p><ol><li>The publication counts reported events rather than consistently identifying unique affected people.<\/li><li>One person may have reported several symptoms.<\/li><li>Not every event was causally attributed to saffron.<\/li><li>Trials used different doses and preparations.<\/li><li>The duration and intensity of monitoring varied.<\/li><li>Conditions and participant populations differed substantially.<\/li><li>No formal meta-analysis of the side-effect rate was performed.<\/li><li>Some mild symptoms may not have been fully recorded.<\/li><\/ol>\n<aside class=\"academy-note\"><strong>How to interpret the number<\/strong><p>The trials with safety information documented 441 events among 2,520 saffron participants. The resulting descriptive figure does not show how many people had an event demonstrably caused by saffron.<\/p><p>Saying \u201cone in six people gets side effects from saffron\u201d would therefore not be scientifically justified.<\/p><\/aside>\n<h2 id=\"symptoms\">Which symptoms were reported most often?<\/h2><p>Gastrointestinal symptoms were the most frequently reported group. Neurological symptoms, including headache, fatigue, dizziness and sleep changes, followed.<\/p>\n<div class=\"academy-table\"><table><thead><tr><th scope=\"col\">Group<\/th><th scope=\"col\">Examples<\/th><th scope=\"col\">Reported events<\/th><\/tr><\/thead><tbody><tr><td>Gastrointestinal<\/td><td>Nausea, vomiting, abdominal pain, diarrhoea, constipation, reflux, dry mouth, bloating and appetite changes<\/td><td>171<\/td><\/tr><tr><td>Neurological<\/td><td>Headache, fatigue, dizziness, insomnia, vivid dreams and sedation<\/td><td>146<\/td><\/tr><tr><td>Psychiatric<\/td><td>Nervousness, irritability, restlessness, anxiety and hypomania<\/td><td>32<\/td><\/tr><tr><td>Cardiovascular<\/td><td>Chest pain, palpitations and tachycardia<\/td><td>Rare<\/td><\/tr><tr><td>Other<\/td><td>Itching, sweating, cough, joint pain, allergic reactions or gum bleeding<\/td><td>Sporadic<\/td><\/tr><\/tbody><\/table><\/div>\n<p>Of the 441 recorded events, approximately 38.8% were gastrointestinal and 33.1% neurological. Most were described as mild to moderate. These percentages describe the distribution of events, not the proportion of all saffron users affected.<\/p><p>For a broader overview of symptoms, risk groups and excessive amounts, see <a href=\"https:\/\/www.saffrona.eu\/en\/saffron-safety\/\" target=\"_blank\" rel=\"noopener\">saffron side effects and safety<\/a>.<\/p>\n<h2>Were the events actually caused by saffron?<\/h2><p>In many cases, causality was not established. An event during a trial may be related to the product, an underlying illness, another medicine or an independent cause.<\/p><p>For example, a study in older adults recorded serious events including cancer, pneumonia, heart-valve surgery and pancreatitis. The investigators did not consider those serious events a consequence of saffron supplementation.<\/p><p>Headache, nausea, sleep problems and fatigue also occurred in some control groups. These are nonspecific symptoms with many possible causes. The review therefore shows <strong>what was observed during saffron use<\/strong>, rather than proving that saffron caused every event.<\/p>\n<h2>Were events more common with saffron than in control groups?<\/h2><p>The available raw counts do not allow a reliable overall comparison for or against saffron. In the 44 trials reporting events, the review assembled these totals:<\/p>\n<div class=\"academy-table\"><table><thead><tr><th scope=\"col\">Group<\/th><th scope=\"col\">Participants<\/th><th scope=\"col\">Reported events<\/th><\/tr><\/thead><tbody><tr><td>Saffron groups<\/td><td>1,479<\/td><td>441<\/td><\/tr><tr><td>Control groups<\/td><td>1,202<\/td><td>531<\/td><\/tr><\/tbody><\/table><\/div>\n<p>Proportionally more events were recorded in the control groups. This does not establish that saffron is generally better tolerated than placebo or medicines.<\/p><p>Some controls received active drugs, including antidepressants with known side effects. Monitoring methods also differed. Expectations may contribute through the nocebo effect: people can develop or notice symptoms more strongly when they expect negative effects.<\/p><p>No formal comparative meta-analysis was performed, so these totals remain descriptive.<\/p>\n<h2 id=\"products\">Do saffron powder and extracts differ in tolerability?<\/h2><p>The review found no clear pattern showing different event frequencies for saffron powder, aqueous extracts or hydroalcoholic extracts. This does not mean that all preparations are equivalent.<\/p><p>Many studies did not adequately describe the plant part, extraction method, solvent, extract concentration, crocin content, safranal content, picrocrocin content or chromatographic profile.<\/p><p>Without consistent characterisation, study products cannot be reliably compared. Results for one extract do not automatically apply to whole threads, powder or another commercial preparation.<\/p>\n<h2>Was there a clear relationship between dose and symptoms?<\/h2><p>No clear, consistent increase in adverse events was observed as doses rose within the commonly studied range of about 15\u2013100 milligrams per day.<\/p><p>This does not prove that every dose in that range is safe for everyone. The products and studies differed too much to establish a definitive limit.<\/p><p>Some small trials used amounts up to 400 milligrams daily. Although they did not show a clear concentration of serious events, their small samples and short durations could not reliably exclude rare risks.<\/p><p><strong>The review cannot establish a scientifically confirmed maximum daily dose.<\/strong> A milligram amount of extract also cannot simply be equated with the same weight of whole saffron threads. See our guide to <a href=\"https:\/\/www.saffrona.eu\/en\/saffron-dosage\/\" target=\"_blank\" rel=\"noopener\">culinary amounts, extracts and saffron dosage<\/a> for these distinctions.<\/p>\n<h2>What do we know about long-term tolerability?<\/h2><p>Some trials lasted up to twelve months, but robust evidence on use over several years is lacking. Within the available trials, there was no clear pattern of accumulating symptoms through twelve months. That observation has important limits:<\/p><ul><li>Many trials were much shorter.<\/li><li>Some had small samples, making rare events difficult to detect.<\/li><li>Safety monitoring was not standardised.<\/li><li>Different extracts make comparison difficult.<\/li><li>Very long-term or delayed events were scarcely investigated.<\/li><\/ul><p>Larger studies with active safety monitoring and consistently characterised products are needed.<\/p>\n<figure><img decoding=\"async\" src=\"https:\/\/www.saffrona.eu\/en\/wp-content\/uploads\/2026\/08\/Safran-Vertraeglichkeit.jpeg\" alt=\"Saffron threads accompanying a scientific review of tolerability in 102 clinical trials\" loading=\"lazy\"><figcaption>Clinical safety evidence depends on how products and adverse events are recorded.<\/figcaption><\/figure>\n<h2 id=\"medicines\">What does the saffron and rivaroxaban case report show?<\/h2><p>The review includes one case report of bleeding during concurrent use of a saffron preparation and rivaroxaban. A single case can signal a possible concern, but it cannot prove a general interaction.<\/p><p>The report describes a 64-year-old man with non-valvular atrial fibrillation who developed acute bleeding while taking rivaroxaban and a saffron supplement. His condition improved after discontinuation, and the investigators reported signs of impaired platelet function.<\/p><p>The case cannot establish how often this might occur, whether it occurs with other anticoagulants, the role of the supplement\u2019s dose and composition, or whether saffron alone would have caused bleeding.<\/p><p>Despite that uncertainty, the case is clinically relevant. People using rivaroxaban or other anticoagulant or antiplatelet medicines should not independently add high-dose saffron preparations. German consumer guidance also notes that supplements and herbal products may cause <a href=\"https:\/\/www.verbraucherzentrale.de\/wissen\/lebensmittel\/nahrungsergaenzungsmittel\/wechsel-und-nebenwirkung-gegenanzeige-was-nahrungsergaenzung-verschweigt-50991\" target=\"_blank\" rel=\"noopener\">interactions with medicines<\/a>.<\/p>\n<h2>For whom are safety data still insufficient?<\/h2><p>Caution is appropriate when evidence is limited or other risk factors are present. The authors particularly discuss:<\/p><h3>People taking anticoagulant medicines<\/h3><p>The rivaroxaban case and experimental findings on platelet aggregation justify caution. The magnitude of any risk is unknown.<\/p><h3>Older adults with several conditions<\/h3><p>Age, other illnesses and multiple medicines may increase the risk of adverse events and interactions.<\/p><h3>People with psychiatric conditions<\/h3><p>Sleep changes, restlessness, irritability and hypomania were reported occasionally. Whether particular patient groups are more susceptible requires further study.<\/p><h3>Pregnancy and breastfeeding<\/h3><p>Evidence is insufficient to reliably assess therapeutic saffron extracts during pregnancy or breastfeeding. Culinary use and concentrated preparations must be considered separately. Read more about <a href=\"https:\/\/www.saffrona.eu\/en\/saffron-in-pregnancy\/\" target=\"_blank\" rel=\"noopener\">saffron in pregnancy<\/a>.<\/p><h3>High doses or combinations of products<\/h3><p>Robust safety data are lacking for high daily amounts, prolonged use and combinations with other bioactive preparations.<\/p>\n<h2 id=\"limits\">What questions does the review leave unanswered?<\/h2><ul><li>How many individuals experience a side effect actually caused by saffron?<\/li><li>Which events have a clearly established causal relationship?<\/li><li>Which extract is best tolerated?<\/li><li>Is there a definitive safe maximum dose?<\/li><li>How safe is use over several years?<\/li><li>How common are rare or delayed events?<\/li><li>Which interactions occur with individual medicines?<\/li><li>How safe are therapeutic products during pregnancy or breastfeeding?<\/li><li>Does tolerability reliably differ by age, illness or sex?<\/li><li>How do crocin, safranal and picrocrocin concentrations affect safety?<\/li><\/ul><p>These gaps do not prove a hidden risk. They identify questions that the available evidence cannot answer reliably.<\/p>\n<h2>What are the review\u2019s main limitations?<\/h2><p>The greatest limitation is substantial heterogeneity. Doses, formulations, duration, populations and monitoring differed markedly. Other limitations include:<\/p><ul><li>No adverse-event information in 23 of 102 trials.<\/li><li>No formal meta-analysis.<\/li><li>Small samples in many studies.<\/li><li>Sometimes passive monitoring of mild symptoms.<\/li><li>Often inadequate descriptions of composition and extraction methods.<\/li><li>Inconsistent separation of events by severity and possible causality.<\/li><li>Limited ability to detect rare events in small or short trials.<\/li><li>A literature search ending in August 2024.<\/li><li>Risk-of-bias assessments that were often not consistently low.<\/li><\/ul><p>The review is valuable as an overview of the evidence, rather than a definitive measurement of every risk.<\/p>\n<h2>What do the findings mean for saffron as a spice?<\/h2><p>The results should not be applied indiscriminately to ordinary culinary use. Most included studies examined measured powders or extracts in a medical or supplement context.<\/p>\n<div class=\"academy-table\"><table><thead><tr><th scope=\"col\">Use<\/th><th scope=\"col\">Characteristics<\/th><\/tr><\/thead><tbody><tr><td>Threads in food<\/td><td>A small culinary amount, often shared across portions<\/td><\/tr><tr><td>Powder in capsules<\/td><td>A deliberately measured daily amount<\/td><\/tr><tr><td>Extract<\/td><td>A concentrated preparation with a product-dependent constituent profile<\/td><\/tr><tr><td>Standardised extract<\/td><td>Defined levels of selected constituents, without automatic equivalence to other extracts<\/td><\/tr><\/tbody><\/table><\/div>\n<p>Occasional seasoning involves a different exposure from taking a concentrated product daily. Safety findings for one extract cannot automatically be transferred to every other extract or directly to saffron threads.<\/p>\n<h2>What does this review add?<\/h2><p>The work systematically brings together adverse events documented in human studies of saffron-only preparations. Earlier reviews primarily considered possible effects in particular conditions.<\/p><p>Its contribution is the wider perspective: combining 102 trials, exposing gaps in safety reporting, grouping events by body system, documenting inconsistent product characterisation, clarifying the limits of the 17.5% figure, and highlighting the need for active pharmacovigilance and research on long-term use and medicine interactions.<\/p><p>It therefore adds a methodological question to general information about side effects: <strong>how reliable is the evidence behind statements about saffron tolerability?<\/strong><\/p>\n<h2 id=\"faq\">Frequently asked questions<\/h2>\n<details><summary>Was saffron well tolerated in clinical trials?<\/summary><p>It was generally well tolerated in the reviewed trials. Most documented symptoms were mild to moderate and temporary. This does not establish absolute safety for every person and dose.<\/p><\/details>\n<details><summary>Does 17.5% mean one in six people has side effects?<\/summary><p>No. The figure comes from 441 events among 2,520 participants. Events are not automatically caused by saffron, and individuals may have reported more than one.<\/p><\/details>\n<details><summary>Were events more common than in control groups?<\/summary><p>Proportionally more events were reported in the assembled control-group counts. Different treatments, populations and monitoring methods prevent a general conclusion that saffron is better tolerated.<\/p><\/details>\n<details><summary>Are extracts as well tolerated as whole threads?<\/summary><p>No blanket conclusion is possible. Concentration, manufacturing and composition differ, and results for one product do not automatically apply to others.<\/p><\/details>\n<details><summary>Is there a scientifically established safe maximum dose?<\/summary><p>No. The absence of a clear dose-related increase in the commonly studied 15\u2013100 milligram range does not establish a definitive safe maximum.<\/p><\/details>\n<details><summary>Has saffron been studied long term?<\/summary><p>Some studies lasted twelve months. Evidence on several years of daily use, rare events and delayed effects remains insufficient.<\/p><\/details>\n<details><summary>Can saffron interact with rivaroxaban?<\/summary><p>A case report describes acute bleeding during concurrent use. It raises a possible concern but does not establish a general interaction or its frequency.<\/p><\/details>\n<details><summary>Are gastrointestinal symptoms common?<\/summary><p>They were the most frequently reported event group. The review cannot reliably establish their frequency among individual users or how often saffron was the cause.<\/p><\/details>\n<details><summary>Is saffron safe during pregnancy?<\/summary><p>Safety evidence for high-dose or therapeutic preparations during pregnancy and breastfeeding is insufficient. Small culinary amounts and concentrated extracts require separate consideration.<\/p><\/details>\n<details><summary>When should someone seek medical advice?<\/summary><p>Unusual bleeding, pronounced cardiovascular symptoms, allergic reactions or marked psychological changes warrant medical advice, especially when medicines are also being taken. Acute or severe symptoms require immediate medical assistance.<\/p><\/details>\n<h2>Scientific conclusion<\/h2><h3>What we know<\/h3><p>Saffron-only preparations were generally well tolerated in many clinical trials. The most frequently documented events were gastrointestinal symptoms, headache, fatigue, dizziness and sleep changes. Most were mild to moderate and temporary.<\/p><h3>What remains uncertain<\/h3><p>The precise individual side-effect rate is unknown. The 17.5% figure is not a causally confirmed frequency. A definitive maximum dose, safety over several years and the risks of specific medicine interactions also remain uncertain.<\/p><h3>What future research should address<\/h3><p>Studies should actively record events using consistent criteria and precisely document plant material, extraction methods and crocin, safranal and picrocrocin content. Larger, longer studies are particularly needed for older adults, people taking several medicines, and pregnancy and breastfeeding.<\/p><p>The evidence supports neither alarm nor an unrestricted assurance of safety. Saffron appears mostly well tolerated at the amounts commonly studied, but product-specific safety during prolonged use or concurrent medication requires closer investigation.<\/p><aside class=\"academy-note\"><p><em>This article provides scientific information and does not replace individual medical advice.<\/em><\/p><\/aside>\n<h2>Sources and further reading<\/h2><ol><li>Hasheminasab FS, Hajimonfarednejad M, Najibi SM, Hashempur MH. <em>Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence.<\/em> Health Science Reports. 2026;9:e72212. <a href=\"https:\/\/doi.org\/10.1002\/hsr2.72212\" target=\"_blank\" rel=\"noopener\">doi:10.1002\/hsr2.72212<\/a>.<\/li><li>Verbraucherzentrale: <a href=\"https:\/\/www.verbraucherzentrale.de\/wissen\/lebensmittel\/nahrungsergaenzungsmittel\/wechsel-und-nebenwirkung-gegenanzeige-was-nahrungsergaenzung-verschweigt-50991\" target=\"_blank\" rel=\"noopener\">German consumer information on supplement side effects and interactions<\/a>.<\/li><li>German Society for Rheumatology and Clinical Immunology: <a href=\"https:\/\/www.dgrh.de\/lesen\/empfehlungen\/komplementaere-ansaetze\/safran\/\" target=\"_blank\" rel=\"noopener\">scientific assessment of saffron preparations in rheumatic conditions<\/a>.<\/li><\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>The short answer Saffron was generally well tolerated in most of the clinical studies reviewed. A systematic review published in 2026 examined 102 clinical trials&#8230;<\/p>\n","protected":false},"author":1,"featured_media":3085,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[395],"tags":[],"class_list":["post-3083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saffron-side-effects-and-safety"],"_links":{"self":[{"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/posts\/3083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/comments?post=3083"}],"version-history":[{"count":3,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/posts\/3083\/revisions"}],"predecessor-version":[{"id":3755,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/posts\/3083\/revisions\/3755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/media\/3085"}],"wp:attachment":[{"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/media?parent=3083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/categories?post=3083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saffrona.eu\/en\/wp-json\/wp\/v2\/tags?post=3083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}